Investor Presentaiton

hACE2 Virus copies/ug (Log 10) SNS812 Virus Inhibition - in - in vivo Prophylatic Treatment Prevented Virus Infection ONENESS Prophylatic -D3 -D2 -D1 DO D1 D2 Viral titer Original strain(B) analysis (Lung) P < 0.0001 PFU/g (Log 10) N 8- P < 0.0001 Control SNS812 Viral RNA reduced 99.95% -Data submitted for publication- Control SNS812 Infectious virions Complete inhibition Virus copies/ug (Log 10) Prophylatic -D3 -D2 -D1 DO D1 D2 Viral titer analysis (Lung) hACE2 P < 0.0001 Delta strain(B.1.617.2) PFU/g (Log 10) 8- P < 0.0001 Control SNS812 Viral RNA Reduced 98.3% Control SNS812 Infectious virions Complete inhibition | 30

View entire presentation